New hope for rare hormone disorder: Higher-Dose drug trial underway
Disease control
Recruiting now
This study tests a daily injection of palopegteriparatide at doses above 30 mcg in adults with hypoparathyroidism, a condition where the body doesn't make enough parathyroid hormone. The goal is to see if higher doses can safely control calcium levels without needing extra vitami…
Phase: PHASE3 • Sponsor: Ascendis Pharma Bone Diseases A/S • Aim: Disease control
Last updated May 26, 2026 06:18 UTC